| Literature DB >> 26930275 |
Anna A Shvedova1,2, Naveena Yanamala1, Elena R Kisin1, Timur O Khailullin2,3, M Eileen Birch4, Liliya M Fatkhutdinova3.
Abstract
BACKGROUND: As the application of carbon nanotubes (CNT) in consumer products continues to rise, studies have expanded to determine the associated risks of exposure on human and environmental health. In particular, several lines of evidence indicate that exposure to multi-walled carbon nanotubes (MWCNT) could pose a carcinogenic risk similar to asbestos fibers. However, to date the potential markers of MWCNT exposure are not yet explored in humans.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26930275 PMCID: PMC4773015 DOI: 10.1371/journal.pone.0150628
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Transmission electron micrographs of samples collected in MWCNT facilities.
TEM images of filters collected from personal breathing zone sampling showing: A, more dispersed MWCNT particles; B-C, agglomerated structures from potentially exposed groups, and D, a media blank (stored in a clean room).
Fig 2An overall schema summarizing the integrated bioinformatics analysis of differentially expressed ncRNAs and mRNAs to determine their potential relationships and interactions in MWCNT exposed and non-exposed workers.
Elemental carbon (EC) concentrations found for personal breathing zone (PBZs) samples from workers performing different tasks.
| Process | EC inhalable conc., μg/m3 | EC respirable conc., μg/m3 | %respirable fraction |
|---|---|---|---|
| Harvesting | 29.6 | 6.11 | 20.65 |
| Mechanical grinding | 2.05 | 2.03 | 99.03 |
| Packaging | 25.3 | 2.65 | 10.48 |
| Laboratory handling | 0.71 | 0.54 | 76.06 |
Calculated inhalable (I) and respirable (R) elemental carbon (EC) concentrations of workforce and their approximate lung burdens estimated using MPPD (v.2.1) modelling software.
| Group | Occupation (sample ID) | Gender | (I) TWA 8hr. EC conc., μg/m3 | (R) TWA 8hr. EC conc., μg/m3 | % respirable | Lung burden per year (μg) | Lung burden per day (μg) | Lung burden per day, mouse (ng) |
|---|---|---|---|---|---|---|---|---|
| TB1 | M | 17.14 | 2.78 | 16.19 | 3949.92 | 15.8 | 7.74 | |
| TB2 | M | 10.37 | 1.75 | 16.86 | 2389.25 | 9.56 | 4.69 | |
| TB3 | M | 3.51 | 0.66 | 18.6 | 808.13 | 3.23 | 1.59 | |
| TB4 | M | 3.51 | 0.66 | 18.6 | 808.13 | 3.23 | 1.59 | |
| TB5 | M | 4.37 | 1.27 | 29.09 | 1005.84 | 4.02 | 1.97 | |
| TB14 | M | 17.14 | 2.78 | 16.19 | 3949.92 | 15.8 | 7.75 | |
| VB1 | M | 4.37 | 1.27 | 29.09 | 1005.84 | 4.02 | 1.97 | |
| VB3 | M | 4.37 | 1.27 | 29.09 | 1005.84 | 4.02 | 1.97 | |
| TB6 | M | - | - | - | - | - | - | |
| TB7 | M | - | - | - | - | - | - | |
| TB9 | M | - | - | - | - | - | - | |
| TB10 | M | - | - | - | - | - | - | |
| TB12 | M | - | - | - | - | - | - | |
| VB2 | M | - | - | - | - | - | - | |
| VB4 | M | - | - | - | - | - | - |
The 8hr time-weighted average (TWA) EC concentrations for each occupation in the exposed group were calculated based on inhalable/respirable EC concentrations of PBZ samples (see Table 1) as well as time spent by the personnel in that particular unit/technological process during a working day.
mRNAs and miRNAs in the blood of MWCNT exposed workers associated with various pulmonary and systemic outcomes.
| MWCNT overall exposure group | MWCNT high exposure group | |
|---|---|---|
| — | ||
| — | — | |
| — | ||
| — | ||
| — | mRNAs: | |
Significantly up- or down-regulated (FC >± 1.5, p<0.05) mRNAs/miRNAs of the overall and high MWCNT exposure groups versus non-exposed workers associated with each outcome were derived using IPA. miRNAs/mRNAs that are known to increase the disease/other outcomes considered are highlighted in bold.
Functional analysis of differentially expressed mRNAs, miRNAs and miRNA-mRNA target pairs in the whole blood of workers exposed to MWCNTs.
| mRNA | miRNAs | miRNA-mRNA targets |
|---|---|---|
| 1. Cancer (1932) | 1. Cancer (19) | 1. Neurological Disease (132) |
| 2. Organismal Injury and Abnormalities (1965) | 2. Gastrointestinal Disease (17) | 2. Psycological Disorders (63) |
| 3. Infectious Diseases (296) | 3. Organismal Injury and Abnormalities (19) | 3. Skeletal & Muscular Disorders (79) |
| 4. Gastrointestinal Disease (1318) | 4. Respiratory Disease (14) | 4. Hereditary Disorder (85) |
| 5. Hematological Disease (390) | 5. Reproductive System Disease (12) | 5. Tumor Morphology (7) |
| 1. Cell Death and Survival (636) | 1. Cellular Movement (10) | 1. RNA Post-transcriptional Modification (27) |
| 2. Protein Synthesis (230) | 2. Cell Development (13) | 2. Cellular Development (60) |
| 3. Gene Expression (413) | 3. Cellular Growth and Proliferation (13) | 3. Cellular Growth and Proliferation (57) |
| 4. Cellular Growth and Proliferation (644) | 4. Cell Death and Survival (8) | 4. Cell to Cell Signaling and Interaction (45) |
| 5. RNA Post-transcriptional Modification (73) | 5. Cell Morphology (4) | 5. Nucleic Acid Metabolism (27) |
| 1. Organismal Survival (442) | 1. Organismal Development (6) | 1. Organismal Survival (138) |
| 2. Organismal Development (404) | 2. Digestive System Development and Function (2) | 2. Tissue Development (53) |
| 3. Tissue Morphology (445) | 3. Hepatic System Development and Function (2) | 3. Auditory and Vestibular System Development and Function (8) |
| 4. Hematological System Development and Function (317) | 4. Organ Development (3) | 4. Hematological System Development and Function (52) |
| 5. Immune Cell Trafficking (161) | 5. Hematopoiesis (3) | 5. Immune Cell Trafficking (16) |
Significantly up- or down-regulated (FC >± 1.5, p<0.05) mRNAs/miRNAs of the high MWCNT exposure group versus non-exposed workers associated with ‘disease and disorder’, ‘cellular and molecular functions’, and ‘physiological system development and function’ were determined using IPA.
Gene Signaling networks of differentially expressed mRNAs and miRNA-mRNA target pairs in the whole blood of workers exposed to MWCNTs.
| Rank | mRNA | miRNA-mRNA targets |
|---|---|---|
| Top Ten Predicted Associated / Related Network Functions (Prediction Score / # of Focus Molecules) | ||
| 1 | Cell Cycle, Cell-To-Cell Signaling and Interaction, Connective Tissue Development and Function (33/35) | Cellular Growth and Proliferation, Gene Expression, Cell Cycle (39/30) |
| 2 | Cell-To-Cell Signaling and Interaction, Carbohydrate Metabolism, Developmental Disorder (29/33) | RNA Post-Transcriptional Modification, Cell Death and Survival, Cellular Compromise (33/27) |
| 3 | Connective Tissue Development and Function, Hematological System Development and Function, Hematopoiesis (29/33) | Cell Death and Survival, Connective Tissue Disorders, Dermatological Diseases and Conditions (29/25) |
| 4 | Developmental Disorder, Hematological Disease, Hereditary Disorder (29/33) | Cellular Function and Maintenance, Cell Morphology, Infectious Diseases (29/25) |
| 5 | Cell-To-Cell Signaling and Interaction, Cellular Movement, Hematological System Development and Function (29/33) | Cell-To-Cell Signaling and Interaction, Drug Metabolism, Small Molecule Biochemistry (27/24) |
| 6 | Cell Cycle, DNA Replication, Recombination, and Repair, Cancer (27/32) | Cell-To-Cell Signaling and Interaction, Cell Morphology, Reproductive System Development and Function (26/23) |
| 7 | Antimicrobial Response, Inflammatory Response, Cellular Function and Maintenance (27/32) | Cardiovascular System Development and Function, Cell-To-Cell Signaling and Interaction, Renal and Urological System Development and Function (26/23) |
| 8 | Skeletal and Muscular System Development and Function, Connective Tissue Development and Function, Tissue Development (27/32) | Cell Cycle, Inflammatory Disease, Ophthalmic Disease (26/23) |
| 9 | Gene Expression, Connective Tissue Development and Function, Organismal Development (27/32) | Cell Cycle, Cellular Development, Hematological System Development and Function (22/21) |
| 10 | Small Molecule Biochemistry, RNA Post-Transcriptional Modification, Drug Metabolism (27/32) | Cancer, Organismal Injury and Abnormalities, Embryonic Development (19/19) |
Fig 3Highest scoring gene molecular networks of mRNAs and miRNA-mRNA target pairs in MWCNT high exposure group.
Gene signaling network analysis by IPA of differentially expressed (A) mRNAs and (B) miRNA-mRNA target pairs in high MWCNT exposure group. The datasets either containing all differentially expressed genes or genes having consistent expression direction based on differentially expressed miRNAs were uploaded into IPA then analyzed with the cutoff criteria of ≥ 1.5 fold change and a p-value < 0.05. Only the network is presented for each group. Intensity of the red (upregulated) or green (down regulated) color of the nodes in the graph indicates level of gene expression.
Fig 4KEGG pathway enrichment analysis of dysregulated genes and miRNA-mRNA target pairs in the MWCNT-exposed workers.
Venn diagrams showing common and unique enriched pathways of (A) up- and down-regulated mRNAs KEGG pathways, and (D) down-regulated mRNAs and miRNA-mRNAs targets identified using micro-TDS and TargetScan algorithms of DIANA-miRPath.
KEGG signaling pathway enrichment of miRNA-mRNA targets in the whole blood of workers exposed to MWCNTs.
| Rank | KEGG pathway | p-value | #genes | #miRNAs |
|---|---|---|---|---|
| 1 | Prion diseases | 1.71E-46 | 2 | 2 |
| 2 | Synthesis and degradation of ketone bodies | 1.87E-08 | 3 | 3 |
| 6 | Thyroid cancer | 4.52E-05 | 3 | 4 |
| 8 | Folate biosynthesis | 0.00027464 | 1 | 1 |
| 14 | Endometrial cancer | 0.00267391 | 3 | 3 |
| 17 | Terpenoid backbone biosynthesis | 0.00321421 | 2 | 2 |
| 21 | Herpes simplex infection | 0.00589366 | 6 | 4 |
| 26 | Fatty acid elongation | 0.02315225 | 1 | 1 |
| 28 | Vasopressin-regulated water reabsorption | 0.03827082 | 2 | 1 |
| 30 | Non-homologous end-joining | 0.0464634 | 1 | 1 |
The KEGG pathway enrichment analysis was performed using DIANA-mirPath [44]. The mRNA targets of significantly up-regulated (FC > 1.5, p<0.05) miRNAs of the high MWCNT exposure group versus non-exposed workers were predicted using TargetScan algorithm and the resulting mRNA target list was further filtered for those with significant down-regulation (FC > 1.5, p<0.05) in the mRNA expression profiles obtained from same samples. The enriched pathways overlapping with those predicted based on all down-regulated mRNAs, using DAVID, are highlighted in bold.
Fig 5The regulatory network of ncRNAs and mRNAs in workers exposed to MWCNTs.
The regulatory networks of significantly dysregulated lncRNAs and mRNAs (p-value<0.05, fold-change>±1.5) having positional and/or functional relationship with (A) up-regulated miRNAs (p<0.05, fold-change>1.5) and (B) down-regulated miRNAs (p>0.05, fold-change>-1.5), generated using IPA. The lncRNAs, represented using red (↓) and green (↑) rectangles and dotted lines, with consistent co-expression as mRNAs and/or containing miRNA target binding sites from starBase v2.0 were manually added to the network.
Real time PCR validation of microarray expression data using select genes in the whole blood of workers exposed to MWCNTs.
| Gene | Microarray Data FC (range) | RT-qPCR Data (range) |
|---|---|---|
| CCND1 | -1.8 (-1.4 to -2.3) | -2 |
| CCND3 | 2.4 (2.8 to 2.0) | 1.64 |
| E2F2 | -5.1 (-2.9 to -8.6) | -1.4 (-2.4 to 1.2) |
| MUC1 | 3.4 (4.9 to 1.9) | 1.6 |
| SOD1 | -6.2 (-3.3 to -7.4) | -1.5 |
| TGFβ1 | -1.4 (-1.3 to -1.5) | 1.5 |
Isolated mRNA was reverse-transcribed and subjected to RT-qPCR reaction with Roche Taqman probes. Data represent Mean fold change values along with their lower and upper limits of expression changes, n = 3.
*p < 0.05.